MicroRNAs as potential biomarkers in adrenocortical cancer: Progress and challenges

Frontiers in Endocrinology

Volumn 6, Issue JAN, 2016, Pages

  Cherradi, Nadia ^a,b,c  

^a INSERM   (France)

^b CEA GRENOBLE   (France)

^c UNIV GRENOBLE ALPES   (France)

Author keywords

Adrenocortical carcinoma; Biomarker; Circulating miRNA; Diagnosis; Prognosis; Therapeutic targets

Indexed keywords

BETA CATENIN; MICRORNA; MICRORNA 195; MICRORNA 210; MICRORNA 335; MICRORNA 483 3P; MICRORNA 483 5P; MICRORNA 503; PROTEIN P53; SOMATOMEDIN B; UNCLASSIFIED DRUG; WNT PROTEIN;

ADRENAL CORTEX CARCINOMA; CANCER PROGNOSIS; CARCINOGENESIS; EPITHELIAL MESENCHYMAL TRANSITION; EXOSOME; HUMAN; MICROARRAY ANALYSIS; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SOMATIC MUTATION; TUMOR MICROENVIRONMENT;

EID: 84962527943     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2015.00195     Document Type: Review

References (145)

1. Allolio B, Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab (2006) 91:2027-37. doi: 10.1210/jc.2005-2639
2. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer (2009) 115:243-50. doi:10.1002/cncr.24698
3. Glover AR, Ip JC, Zhao JT, Soon PS, Robinson BG, Sidhu SB. Current management options for recurrent adrenocortical carcinoma. Onco Targets Ther (2013) 6:635-43. doi:10.2147/OTT.S34956
4. Daffara F, De Francia S, Reimondo G, Zaggia B, Aroasio E, Porpiglia F, et al. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer (2008) 15:1043-53. doi:10.1677/ERC-08-0103
5. Fassnacht M, Hahner S, Polat B, Koschker AC, Kenn W, Flentje M, et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab (2006) 91:4501-4. doi:10.1210/jc.2006-1007
6. Sabolch A, Feng M, Griffith K, Hammer G, Doherty G, Ben-Josef E. Adjuvant and definitive radiotherapy for adrenocortical carcinoma. Int J Radiat Oncol Biol Phys (2011) 80:1477-84. doi:10.1016/j.ijrobp.2010.04.030
7. Habra MA, Ejaz S, Feng L, Das P, Deniz F, Grubbs EG, et al. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab (2013) 98:192-7. doi:10.1210/jc.2012-2367
8. De Francia S, Ardito A, Daffara F, Zaggia B, Germano A, Berruti A, et al. Mitotane treatment for adrenocortical carcinoma: an overview. Minerva Endocrinol (2012) 37:9-23.
9. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 366:2189-97. doi:10.1056/NEJMoa1200966
10. Quinkler M, Hahner S, Wortmann S, Johanssen S, Adam P, Ritter C, et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab (2008) 93:2057-62. doi:10.1210/jc.2007-2564
11. Wortmann S, Quinkler M, Ritter C, Kroiss M, Johanssen S, Hahner S, et al. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol (2010) 162:349-56. doi:10.1530/EJE-09-0804
12. Berruti A, Sperone P, Ferrero A, Germano A, Ardito A, Priola AM, et al. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol (2012) 166:451-8. doi:10.1530/EJE-11-0918
13. Kroiss M, Quinkler M, Johanssen S, Van Erp NP, Lankheet N, Pollinger A, et al. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab (2012) 97:3495-503. doi:10.1210/jc.2012-1419
14. Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, et al. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer (2013) 108:826-30. doi:10.1038/bjc.2013.46
15. Lerario AM, Worden FP, Ramm CA, Hesseltine EA, Stadler WM, Else T, et al. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. Horm Cancer (2014) 5:232-9. doi:10.1007/s12672-014-0182-1
16. Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol (2015) 16:426-35. doi:10.1016/S1470-2045(15)70081-1
17. Giordano TJ, Thomas DG, Kuick R, Lizyness M, Misek DE, Smith AL, et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol (2003) 162:521-31. doi:10.1016/S0002-9440(10)63846-1
18. de Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, Houlgatte R, et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab (2005) 90:1819-29. doi:10.1210/jc.2004-1075
19. Slater EP, Diehl SM, Langer P, Samans B, Ramaswamy A, Zielke A, et al. Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. Eur J Endocrinol (2006) 154:587-98. doi:10.1530/eje.1.02116
20. Fernandez-Ranvier GG, Weng J, Yeh RF, Shibru D, Khafnashar E, Chung KW, et al. Candidate diagnostic markers and tumor suppressor genes for adrenocortical carcinoma by expression profile of genes on chromosome 11q13. World J Surg (2008) 32:873-81. doi:10.1007/s00268-008-9521-0
21. de Reynies A, Assie G, Rickman DS, Tissier F, Groussin L, Rene-Corail F, et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol (2009) 27:1108-15. doi:10.1200/JCO.2008.18.5678
22. Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, Bauersfeld J, et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res (2009) 15:668-76. doi:10.1158/1078-0432.CCR-08-1067
23. Laurell C, Velazquez-Fernandez D, Lindsten K, Juhlin C, Enberg U, Geli J, et al. Transcriptional profiling enables molecular classification of adrenocortical tumours. Eur J Endocrinol (2009) 161:141-52. doi:10.1530/EJE-09-0068
24. Soon PS, Gill AJ, Benn DE, Clarkson A, Robinson BG, Mcdonald KL, et al. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocr Relat Cancer (2009) 16:573-83. doi:10.1677/ERC-08-0237
25. Tombol Z, Szabo PM, Molnar V, Wiener Z, Tolgyesi G, Horanyi J, et al. Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis. Endocr Relat Cancer (2009) 16:895-906. doi:10.1677/ERC-09-0096
26. Assie G, Letouze E, Fassnacht M, Jouinot A, Luscap W, Barreau O, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet (2014) 46:607-12. doi:10.1038/ng.2953
27. Ambros V. The functions of animal microRNAs. Nature (2004) 431:350-5. doi:10.1038/nature02871
28. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res (2009) 19:92-105. doi:10.1101/gr.082701.108
29. Bartel DP. microRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 116:281-97. doi:10.1016/S0092-8674(04)00045-5
30. Vasudevan S. Posttranscriptional upregulation by microRNAs. Wiley Interdiscip Rev RNA (2012) 3:311-30. doi:10.1002/wrna.121
31. Salmanidis M, Pillman K, Goodall G, Bracken C. Direct transcriptional regulation by nuclear microRNAs. Int J Biochem Cell Biol (2014) 54:304-11. doi:10.1016/j.biocel.2014.03.010
32. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, et al. microRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A (2004) 101:11755-60. doi:10.1073/pnas.0404432101
33. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med (2005) 353:1793-801. doi:10.1056/NEJMoa050995
34. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 101:2999-3004. doi:10.1073/pnas.0307323101
35. Lin S, Gregory RI. microRNA biogenesis pathways in cancer. Nat Rev Cancer (2015) 15:321-33. doi:10.1038/nrc3932
36. Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res (2006) 66:1277-81. doi:10.1158/0008-5472.CAN-05-3632
37. Thomson JM, Newman M, Parker JS, Morin-Kensicki EM, Wright T, Hammond SM. Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev (2006) 20:2202-7. doi:10.1101/gad.1444406
38. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature (2009) 460:529-33. doi:10.1038/nature08199
39. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. microRNA expression profiles classify human cancers. Nature (2005) 435:834-8. doi:10.1038/nature03702
40. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 105:10513-8. doi:10.1073/pnas.0804549105
41. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. microRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol (2011) 8:467-77. doi:10.1038/nrclinonc.2011.76
42. Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol (2014) 11:145-56. doi:10.1038/nrclinonc.2014.5
43. Bartel DP. microRNAs: target recognition and regulatory functions. Cell (2009) 136:215-33. doi:10.1016/j.cell.2009.01.002
44. Pasquinelli AE. microRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet (2012) 13:271-82. doi:10.1038/nrg3162
45. Wen D, Danquah M, Chaudhary AK, Mahato RI. Small molecules targeting microRNA for cancer therapy: promises and obstacles. J Control Release (2015) 219:237-47. doi:10.1016/j.jconrel.2015.08.011
46. Doghman M, El Wakil A, Cardinaud B, Thomas E, Wang J, Zhao W, et al. Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Res (2010) 70:4666-75. doi:10.1158/0008-5472.CAN-09-3970
47. Ozata DM, Caramuta S, Velazquez-Fernandez D, Akcakaya P, Xie H, Hoog A, et al. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr Relat Cancer (2011) 18:643-55. doi:10.1530/ERC-11-0082
48. Caramuta S, Lee L, Ozata DM, Akcakaya P, Xie H, Hoog A, et al. Clinical and functional impact of TARBP2 over-expression in adrenocortical carcinoma. Endocr Relat Cancer (2013) 20:551-64. doi:10.1530/ERC-13-0098
49. Glover AR, Zhao JT, Gill AJ, Weiss J, Mugridge N, Kim E, et al. microRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma. Oncotarget (2015) 6:36675-88. doi:10.18632/oncotarget.5383
50. Wu Y, Wang W, Hu W, Xu W, Xiao G, Nie Q, et al. microRNA-205 suppresses the growth of adrenocortical carcinoma SW-13 cells via targeting Bcl-2. Oncol Rep (2015) 34:3104-10. doi:10.3892/or.2015.4295
51. Szabo PM, Butz H, Igaz P, Racz K, Hunyady L, Patocs A. Minireview: miRomics in endocrinology: a novel approach for modeling endocrine diseases. Mol Endocrinol (2013) 27:573-85. doi:10.1210/me.2012-1220
52. Ebert MS, Sharp PA. Emerging roles for natural microRNA sponges. Curr Biol (2010) 20:R858-61. doi:10.1016/j.cub.2010.08.052
53. Sanchez-Mejias A, Tay Y. Competing endogenous RNA networks: tying the essential knots for cancer biology and therapeutics. J Hematol Oncol (2015) 8:30. doi:10.1186/s13045-015-0129-1
54. Glover AR, Zhao JT, Ip JC, Lee JC, Robinson BG, Gill AJ, et al. Long noncoding RNA profiles of adrenocortical cancer can be used to predict recurrence. Endocr Relat Cancer (2015) 22:99-109. doi:10.1530/ERC-14-0457
55. Singh P, Soon PS, Feige JJ, Chabre O, Zhao JT, Cherradi N, et al. Dysregulation of microRNAs in adrenocortical tumors. Mol Cell Endocrinol (2012) 351:118-28. doi:10.1016/j.mce.2011.09.041
56. Igaz P, Igaz I, Nagy Z, Nyiro G, Szabo PM, Falus A, et al. microRNAs in adrenal tumors: relevance for pathogenesis, diagnosis, and therapy. Cell Mol Life Sci (2015) 72:417-28. doi:10.1007/s00018-014-1752-7
57. Soon PS, Tacon LJ, Gill AJ, Bambach CP, Sywak MS, Campbell PR, et al. miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin Cancer Res (2009) 15:7684-92. doi:10.1158/1078-0432.CCR-09-1587
58. Patterson EE, Holloway AK, Weng J, Fojo T, Kebebew E. microRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer (2011) 117:1630-9. doi:10.1002/cncr.25724
59. Chabre O, Libe R, Assie G, Barreau O, Bertherat J, Bertagna X, et al. Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. Endocr Relat Cancer (2013) 20:579-94. doi:10.1530/ERC-13-0051
60. Duregon E, Rapa I, Votta A, Giorcelli J, Daffara F, Terzolo M, et al. microRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations. Hum Pathol (2014) 45:1555-62. doi:10.1016/j.humpath.2014.04.005
61. Feinmesser M, Benbassat C, Meiri E, Benjamin H, Lebanony D, Lebenthal Y, et al. Specific microRNAs differentiate adrenocortical adenomas from carcinomas and correlate with weiss histopathologic system. Appl Immunohistochem Mol Morphol (2015) 23:522-31. doi:10.1097/PAI.0000000000000117
62. Tombol Z, Eder K, Kovacs A, Szabo PM, Kulka J, Liko I, et al. microRNA expression profiling in benign (sporadic and hereditary) and recurring adrenal pheochromocytomas. Mod Pathol (2010) 23:1583-95. doi:10.1038/modpathol.2010.164
63. Schmitz KJ, Helwig J, Bertram S, Sheu SY, Suttorp AC, Seggewiss J, et al. Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours. J Clin Pathology (2011) 64:529-35. doi:10.1136/jcp.2010.085621
64. Meyer-Rochow GY, Jackson NE, Conaglen JV, Whittle DE, Kunnimalaiyaan M, Chen H, et al. microRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocr Relat Cancer (2010) 17:835-46. doi:10.1677/ERC-10-0142
65. Veronese A, Visone R, Consiglio J, Acunzo M, Lupini L, Kim T, et al. Mutated beta-catenin evades a microRNA-dependent regulatory loop. Proc Natl Acad Sci U S A (2011) 108:4840-5. doi:10.1073/pnas.1101734108
66. Veronese A, Lupini L, Consiglio J, Visone R, Ferracin M, Fornari F, et al. Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res (2010) 70:3140-9. doi:10.1158/0008-5472.CAN-09-4456
67. Liu M, Roth A, Yu M, Morris R, Bersani F, Rivera MN, et al. The IGF2 intronic miR-483 selectively enhances transcription from IGF2 fetal promoters and enhances tumorigenesis. Genes Dev (2013) 27:2543-8. doi:10.1101/gad.224170.113
68. Wang C, Sun Y, Wu H, Zhao D, Chen J. Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers. Histopathology (2014) 64:567-76. doi:10.1111/his.12283
69. Song Q, Xu Y, Yang C, Chen Z, Jia C, Chen J, et al. miR-483-5p promotes invasion and metastasis of lung adenocarcinoma by targeting RhoGDI1 and ALCAM. Cancer Res (2014) 74:3031-42. doi:10.1158/0008-5472.CAN-13-2193
70. Sun FL, Dean WL, Kelsey G, Allen ND, Reik W. Transactivation of Igf2 in a mouse model of Beckwith-Wiedemann syndrome. Nature (1997) 389:809-15. doi:10.1038/39797
71. Drelon C, Berthon A, Ragazzon B, Tissier F, Bandiera R, Sahut-Barnola I, et al. Analysis of the role of Igf2 in adrenal tumour development in transgenic mouse models. PLoS One (2012) 7:e44171. doi:10.1371/journal.pone.0044171
72. Heaton JH, Wood MA, Kim AC, Lima LO, Barlaskar FM, Almeida MQ, et al. Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and beta-catenin. Am J Pathol (2012) 181:1017-33. doi:10.1016/j.ajpath.2012.05.026
73. Zhao JJ, Yang J, Lin J, Yao N, Zhu Y, Zheng J, et al. Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. Childs Nerv Syst (2009) 25:13-20. doi:10.1007/s00381-008-0701-x
74. Corbetta S, Vaira V, Guarnieri V, Scillitani A, Eller-Vainicher C, Ferrero S, et al. Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. Endocr Relat Cancer (2010) 17:135-46. doi:10.1677/ERC-09-0134
75. Zhou B, Ma R, Si W, Li S, Xu Y, Tu X, et al. microRNA-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth. Cancer Lett (2013) 333:159-69. doi:10.1016/j.canlet.2013.01.028
76. Xiao F, Zhang W, Chen L, Chen F, Xie H, Xing C, et al. microRNA-503 inhibits the G1/S transition by downregulating cyclin D3 and E2F3 in hepatocellular carcinoma. J Transl Med (2013) 11:195. doi:10.1186/1479-5876-11-195
77. Zhang Y, Chen X, Lian H, Liu J, Zhou B, Han S, et al. microRNA-503 acts as a tumor suppressor in glioblastoma for multiple antitumor effects by targeting IGF-1R. Oncol Rep (2014) 31:1445-52. doi:10.3892/or.2013.2951
78. Chan YC, Banerjee J, Choi SY, Sen CK. miR-210: the master hypoxamir. Microcirculation (2012) 19:215-23. doi:10.1111/j.1549-8719.2011.00154.x
79. Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell (2009) 35:856-67. doi:10.1016/j.molcel.2009.09.006
80. Cho WC, Chow AS, Au JS. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur J Cancer (2009) 45:2197-206. doi:10.1016/j.ejca.2009.04.039
81. Puissegur MP, Mazure NM, Bertero T, Pradelli L, Grosso S, Robbe-Sermesant K, et al. miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ (2011) 18:465-78. doi:10.1038/cdd.2010.119
82. Malzkorn B, Wolter M, Liesenberg F, Grzendowski M, Stuhler K, Meyer HE, et al. Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol (2010) 20:539-50. doi:10.1111/j.1750-3639.2009.00328.x
83. Satzger I, Mattern A, Kuettler U, Weinspach D, Voelker B, Kapp A, et al. microRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int J Cancer (2010) 126:2553-62. doi:10.1002/ijc.24960
84. Greither T, Grochola LF, Udelnow A, Lautenschlager C, Wurl P, Taubert H. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer (2010) 126:73-80. doi:10.1002/ijc.24687
85. Vaksman O, Stavnes HT, Kaern J, Trope CG, Davidson B, Reich R. miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med (2011) 15:1593-602. doi:10.1111/j.1582-4934.2010.01148.x
86. Neal CS, Michael MZ, Rawlings LH, Van Der Hoek MB, Gleadle JM. The VHL-dependent regulation of microRNAs in renal cancer. BMC Med (2010) 8:64. doi:10.1186/1741-7015-8-64
87. Huang X, Le QT, Giaccia AJ. miR-210-micromanager of the hypoxia pathway. Trends Mol Med (2010) 16:230-7. doi:10.1016/j.molmed.2010.03.004
88. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, et al. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res (2008) 14:1340-8. doi:10.1158/1078-0432.CCR-07-1755
89. Zhang Z, Sun H, Dai H, Walsh RM, Imakura M, Schelter J, et al. microRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle (2009) 8:2756-68. doi:10.4161/cc.8.17.9387
90. Mutharasan RK, Nagpal V, Ichikawa Y, Ardehali H. microRNA-210 is upregulated in hypoxic cardiomyocytes through Akt-and p53-dependent pathways and exerts cytoprotective effects. Am J Physiol Heart Circ Physiol (2011) 301:H1519-30. doi:10.1152/ajpheart.01080.2010
91. Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang Y, et al. Analysis of miR-195 and miR-497 expression, regulation and role in breast cancer. Clin Cancer Res (2011) 17:1722-30. doi:10.1158/1078-0432.CCR-10-1800
92. Ujifuku K, Mitsutake N, Takakura S, Matsuse M, Saenko V, Suzuki K, et al. miR-195, miR-455-3p and miR-10a(*) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett (2010) 296:241-8. doi:10.1016/j.canlet.2010.04.013
93. Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D, et al. Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol (2009) 24:652-7. doi:10.1111/j.1440-1746.2008.05666.x
94. Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM. microRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology (2009) 50:113-21. doi:10.1002/hep.22919
95. Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer (2009) 125:345-52. doi:10.1002/ijc.24390
96. Liu L, Chen L, Xu Y, Li R, Du X. microRNA-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells. Biochem Biophys Res Commun (2010) 400:236-40. doi:10.1016/j.bbrc.2010.08.046
97. Wang F, Zheng Z, Guo J, Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol (2010) 119:586-93. doi:10.1016/j.ygyno.2010.07.021
98. Png KJ, Yoshida M, Zhang XH, Shu W, Lee H, Rimner A, et al. microRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev (2011) 25:226-31. doi:10.1101/gad.1974211
99. Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM, Gao HJ. Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis (2010) 11:50-4. doi:10.1111/j.1751-2980.2009.00413.x
100. Zhang H, Luo XQ, Zhang P, Huang LB, Zheng YS, Wu J, et al. microRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One (2009) 4:e7826. doi:10.1371/journal.pone.0007826
101. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature (2008) 451:147-52. doi:10.1038/nature06487
102. Wang K, Chen X, Zhan Y, Jiang W, Liu X, Wang X, et al. miR-335 inhibits the proliferation and invasion of clear cell renal cell carcinoma cells through direct suppression of BCL-W. Tumour Biol (2015) 36:6875-82. doi:10.1007/s13277-015-3382-6
103. Gao Y, Zeng F, Wu JY, Li HY, Fan JJ, Mai L, et al. miR-335 inhibits migration of breast cancer cells through targeting oncoprotein c-Met. Tumour Biol (2015) 36:2875-83. doi:10.1007/s13277-014-2917-6
104. Streicher KL, Zhu W, Lehmann KP, Georgantas RW, Morehouse CA, Brohawn P, et al. A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth. Oncogene (2012) 31:1558-70. doi:10.1038/onc.2011.345
105. Mueller DW, Rehli M, Bosserhoff AK. miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J Invest Dermatol (2009) 129:1740-51. doi:10.1038/jid.2008.452
106. Benetatos L, Hatzimichael E, Londin E, Vartholomatos G, Loher P, Rigoutsos I, et al. The microRNAs within the DLK1-DIO3 genomic region: involvement in disease pathogenesis. Cell Mol Life Sci (2013) 70:795-814. doi:10.1007/s00018-012-1080-8
107. Teferedegne B, Murata H, Quinones M, Peden K, Lewis AM. Patterns of microRNA expression in non-human primate cells correlate with neoplastic development in vitro. PLoS One (2010) 5:e14416. doi:10.1371/journal.pone.0014416
108. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol (2010) 11:136-46. doi:10.1016/S1470-2045(09)70343-2
109. Luk JM, Burchard J, Zhang C, Liu AM, Wong KF, Shek FH, et al. DLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survival. J Biol Chem (2011) 286:30706-13. doi:10.1074/jbc.M111.229831
110. Ye G, Fu G, Cui S, Zhao S, Bernaudo S, Bai Y, et al. microRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J Cell Sci (2011) 124:359-68. doi:10.1242/jcs.072223
111. Karube Y, Tanaka H, Osada H, Tomida S, Tatematsu Y, Yanagisawa K, et al. Reduced expression of dicer associated with poor prognosis in lung cancer patients. Cancer Sci (2005) 96:111-5. doi:10.1111/j.1349-7006.2005.00015.x
112. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 359:2641-50. doi:10.1056/NEJMoa0803785
113. Ma Z, Swede H, Cassarino D, Fleming E, Fire A, Dadras SS. Up-regulated dicer expression in patients with cutaneous melanoma. PLoS One (2011) 6:e20494. doi:10.1371/journal.pone.0020494
114. Faber C, Horst D, Hlubek F, Kirchner T. Overexpression of dicer predicts poor survival in colorectal cancer. Eur J Cancer (2011) 47:1414-9. doi:10.1016/j.ejca.2011.01.006
115. Muralidhar B, Goldstein LD, Ng G, Winder DM, Palmer RD, Gooding EL, et al. Global microRNA profiles in cervical squamous cell carcinoma depend on Drosha expression levels. J Pathol (2007) 212:368-77. doi:10.1002/path.2179
116. Sand M, Gambichler T, Skrygan M, Sand D, Scola N, Altmeyer P, et al. Expression levels of the microRNA processing enzymes Drosha and dicer in epithelial skin cancer. Cancer Invest (2010) 28:649-53. doi:10.3109/07357901003630918
117. Sugito N, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Kurehara H, et al. RNASEN regulates cell proliferation and affects survival in esophageal cancer patients. Clin Cancer Res (2006) 12:7322-8. doi:10.1158/1078-0432.CCR-06-0515
118. de Sousa GR, Ribeiro TC, Faria AM, Mariani BM, Lerario AM, Zerbini MC, et al. Low DICER1 expression is associated with poor clinical outcome in adrenocortical carcinoma. Oncotarget (2015) 6:22724-33. doi:10.18632/oncotarget.4261
119. Faria AM, Sbiera S, Ribeiro TC, Soares IC, Mariani BM, Freire DS, et al. Expression of LIN28 and its regulatory microRNAs in adult adrenocortical cancer. Clin Endocrinol (Oxf) (2015) 82:481-8. doi:10.1111/cen.12607
120. Tsialikas J, Romer-Seibert J. LIN28: roles and regulation in development and beyond. Development (2015) 142:2397-404. doi:10.1242/dev.117580
121. Turchinovich A, Weiz L, Burwinkel B. Extracellular miRNAs: the mystery of their origin and function. Trends Biochem Sci (2012) 37:460-5. doi:10.1016/j.tibs.2012.08.003
122. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem (2010) 285:17442-52. doi:10.1074/jbc.M110.107821
123. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res (2011) 39:7223-33. doi:10.1093/nar/gkr254
124. Cherradi N, Bideau M, Arnaudeau S, Demaurex N, James RW, Azhar S, et al. Angiotensin II promotes selective uptake of high density lipoprotein cholesterol esters in bovine adrenal glomerulosa and human adrenocortical carcinoma cells through induction of scavenger receptor class B type I. Endocrinology (2001) 142:4540-9. doi:10.1210/endo.142.10.8412
125. Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP, Van Zandwijk N, et al. Haemolysis during sample preparation alters microRNA content of plasma. PLoS One (2011) 6:e24145. doi:10.1371/journal.pone.0024145
126. McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem (2011) 57:833-40. doi:10.1373/clinchem.2010.157198
127. Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (2012) 5:492-7. doi:10.1158/1940-6207.CAPR-11-0370
128. Patel D, Boufraqech M, Jain M, Zhang L, He M, Gesuwan K, et al. miR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors. Surgery (2013) 154:1224-8. doi:10.1016/j.surg.2013.06.022
129. Szabo DR, Luconi M, Szabo PM, Toth M, Szucs N, Horanyi J, et al. Analysis of circulating microRNAs in adrenocortical tumors. Lab Invest (2014) 94:331-9. doi:10.1038/labinvest.2013.148
130. Wang K, Zhang S, Weber J, Baxter D, Galas DJ. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res (2010) 38:7248-59. doi:10.1093/nar/gkq601
131. Hristov M, Erl W, Linder S, Weber PC. Apoptotic bodies from endothelial cells enhance the number and initiate the differentiation of human endothelial progenitor cells in vitro. Blood (2004) 104:2761-6. doi:10.1182/blood-2003-10-3614
132. Melo SA, Sugimoto H, O'connell JT, Kato N, Villanueva A, Vidal A, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell (2014) 26:707-21. doi:10.1016/j.ccell.2014.09.005
133. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol (2007) 9:654-9. doi:10.1038/ncb1596
134. Luga V, Zhang L, Viloria-Petit AM, Ogunjimi AA, Inanlou MR, Chiu E, et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell (2012) 151:1542-56. doi:10.1016/j.cell.2012.11.024
135. Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell (2014) 25:501-15. doi:10.1016/j.ccr.2014.03.007
136. Le MT, Hamar P, Guo C, Basar E, Perdigao-Henriques R, Balaj L, et al. miR-200-containing extracellular vesicles promote breast cancer cell metastasis. J Clin Invest (2014) 124:5109-28. doi:10.1172/JCI75695
137. Challagundla KB, Wise PM, Neviani P, Chava H, Murtadha M, Xu T, et al. Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy. J Natl Cancer Inst (2015) 107:1-13. doi:10.1093/jnci/djv135
138. Bader AG, Brown D, Stoudemire J, Lammers P. Developing therapeutic microRNAs for cancer. Gene Ther (2011) 18:1121-6. doi:10.1038/gt.2011.79
139. Ebert MS, Sharp PA. microRNA sponges: progress and possibilities. RNA (2010) 16:2043-50. doi:10.1261/rna.2414110
140. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet (2006) 38:1060-5. doi:10.1038/ng1855
141. Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA. J Cell Mol Med (2009) 13:39-53. doi:10.1111/j.1582-4934.2008.00556.x
142. Janssen HL, Kauppinen S, Hodges MR. HCV infection and miravirsen. N Engl J Med (2013) 369:878. doi:10.1056/NEJMc1307787
143. van Rooij E, Olson EN. microRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov (2012) 11:860-72. doi:10.1038/nrd3864
144. MacDiarmid JA, Mugridge NB, Weiss JC, Phillips L, Burn AL, Paulin RP, et al. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell (2007) 11:431-45. doi:10.1016/j.ccr.2007.03.012
145. Kao SC, Fulham M, Wong K, Cooper W, Brahmbhatt H, Macdiarmid J, et al. A significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma. Am J Respir Crit Care Med (2015) 191:1467-9. doi:10.1164/rccm.201503-0461LE